Literature DB >> 10454527

Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate.

S K Sharma1, P Zahradka, D Chapman, H Kumamoto, N Takeda, N S Dhalla.   

Abstract

Antiproliferative behavior of sarpogrelate (Anplag, MCI-9042, (+/-)-1-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-3-(dimethylamino)-2-pro pyl hydrogen succinate hydrochloride), a serotonin 2A (5-HT2A) receptor antagonist, was established using radioactive incorporation of [(3)H]thymidine, [(3)H]uridine, and [(3)H]phenylalanine in cultured rat aortic smooth muscle cells in response to a 5-HT-induced cytokine trigger. Fluorescence-activated cell sorting was used to confirm these observations. 5-HT-induced DNA, RNA, and protein synthesis were inhibited maximally at a concentration of 1 microM sarpogrelate. Although other cytokines such as platelet-derived growth factor and endothelin also induced DNA, RNA, and protein synthesis in rat aortic smooth muscle cells, cell proliferation was not influenced by sarpogrelate, even at large pharmacological concentrations (10 microM). Sarpogrelate's antiproliferative actions were found to be more potent than ketanserin. These data indicate that sarpogrelate operates as a specific inhibitor of 5-HT-mediated cell proliferation and is a good candidate for preventing serotonin-induced neointimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454527

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Effect of sarpogrelate on cardiovascular disorders.

Authors:  Chihiro Shikata; Masami Nemoto; Takanori Ebisawa; Akihiro Nishiyama; Nobuakira Takeda
Journal:  Exp Clin Cardiol       Date:  2011

2.  Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure.

Authors:  Günay Yetik Anacak; Levent Ustünes; Ozlem Yilmaz Dilsiz; Adviye Ergul
Journal:  Vascul Pharmacol       Date:  2010-08-12       Impact factor: 5.773

Review 3.  Pulmonary hypertension: therapeutic targets within the serotonin system.

Authors:  Y Dempsie; M R MacLean
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

4.  Risk factors for coronary artery sclerosis in patients with diabetes.

Authors:  Akihiro Nishiyama; Chihiro Shikata; Nobuaki Kimura; Akio Imanishi; Noriyuki Hirai; Makoto Ohta; Nobuakira Takeda
Journal:  Exp Clin Cardiol       Date:  2005

5.  Effects of the 5-HT2A Antagonist Sarpogrelate on Walking Ability in Patients with Intermittent Claudication as Measured Using the Walking Impairment Questionnaire.

Authors:  Hiroshi Matsuo; Hiroshi Shigematsu
Journal:  Ann Vasc Dis       Date:  2008-09-25

6.  Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats.

Authors:  Dhananjay N Umrani; Dipali N Bodiwala; Ramesh K Goyal
Journal:  Mol Cell Biochem       Date:  2003-07       Impact factor: 3.396

7.  The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial.

Authors:  Kyungil Park; Woo-Young Chung; Jae-Bin Seo; Sang-Hyun Kim; Joo-Hee Zo; Myung-A Kim; Young-Bae Park
Journal:  Trials       Date:  2010-12-20       Impact factor: 2.279

8.  Suppression of high lipid diet induced by atherosclerosis sarpogrelate.

Authors:  Yan-Jun Xu; Ming Zhang; Lei Ji; Vijayan Elimban; Li Chen; Naranjan S Dhalla
Journal:  J Cell Mol Med       Date:  2012-10       Impact factor: 5.310

9.  Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results.

Authors:  Yue-Xin Chen; Wen-Da Wang; Xiao-Jun Song; Yong-Quan Gu; Hong-Yan Tian; He-Jie Hu; Ji-Chun Zhao; Xiao-Qiang Li; Chang-Wei Liu
Journal:  Chin Med J (Engl)       Date:  2015-06-20       Impact factor: 2.628

10.  Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.

Authors:  Santosh K Sanganalmath; Andrea P Babick; Judit Barta; Hideo Kumamoto; Nobuakiya Takeda; Naranjan S Dhalla
Journal:  J Cell Mol Med       Date:  2007-12-14       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.